Whitefort Capital Management, LP 13D and 13G filings for Arbutus Biopharma Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-21 09:00 am Purchase |
2025-02-20 | 13D | Arbutus Biopharma Corporation ABUS |
Whitefort Capital Management, LP | 13,307,967 7.000% |
440,000 (+3.42%) |
Filing |
| 2024-05-17 09:03 am Unchanged |
2024-05-17 | 13D | Arbutus Biopharma Corporation ABUS |
Whitefort Capital Management, LP | 12,867,967 6.800% |
0 (Unchanged) |
Filing |
| 2024-05-09 08:00 am Sale |
2024-05-02 | 13D | Arbutus Biopharma Corporation ABUS |
Whitefort Capital Management, LP | 12,867,967 6.800% |
-329,095 (-2.49%) |
Filing |
| 2024-02-14 4:38 pm Purchase |
2023-12-31 | 13G | Arbutus Biopharma Corporation ABUS |
Whitefort Capital Management, LP | 13,197,062 7.900% |
3,183,163 (+31.79%) |
Filing |
| 2023-09-11 5:07 pm Purchase |
2023-09-01 | 13G | Arbutus Biopharma Corporation ABUS |
Whitefort Capital Management, LP | 10,013,899 6.000% |
10,013,899 (New Position) |
Filing |